Department of Psychiatry, University of Bologna, Viale C. Pepoli 5, Bologna, Italy.
J Psychopharmacol. 2010 Dec;24(12):1747-54. doi: 10.1177/0269881109353463. Epub 2010 Feb 8.
Brain-derived neurotrophic factor is a candidate gene for response to antidepressant treatment. However, response to pharmacological treatments is moderated by both genetic and other factors within individuals. For example, there is evidence of an influence of the temperamental trait of harm avoidance on the outcome of depressive disorders. In the present study we aimed to investigate the effect of the brain-derived neurotrophic factor gene on medium-term outcome in a naturalistic sample of 86 depressed bipolar spectrum patients, taking into account harm avoidance. Both single marker and haplotypes were significantly associated with severity of depression at month 6 after treatment initiation. The haplotype comprising the A-C alleles was associated with a poorer outcome. Harm avoidance maintained a significant effect on depressive outcome in bipolar disorder, independently from brain-derived neurotrophic factor genotypes. However, harm avoidance s influence appeared to be more consistent in patients carrying the protective G-T combination of alleles. Our results indicate brain-derived neurotrophic factor as involved in the outcome of depression in bipolar disorder. Harm avoidance did not interact with brain-derived neurotrophic factor genotypes, though its effect was still significant. Given that many factors may influence response to pharmacological treatments, studies that consider personality and other individual characteristics are warranted also in pharmacogenetic investigations.
脑源性神经营养因子是抗抑郁治疗反应的候选基因。然而,个体的遗传和其他因素也会影响药物治疗的反应。例如,有证据表明,气质特征中的回避危险对抑郁障碍的结局有影响。在本研究中,我们旨在探讨脑源性神经营养因子基因对 86 例自然发生的抑郁双相谱患者在治疗开始后 6 个月的中期结局的影响,同时考虑回避危险。单标记和单倍型均与治疗后 6 个月的抑郁严重程度显著相关。包含 A-C 等位基因的单倍型与较差的预后相关。回避危险在双相障碍中对抑郁结局有独立的影响,不受脑源性神经营养因子基因型的影响。然而,在携带保护性 G-T 等位基因组合的患者中,回避危险的影响似乎更为一致。我们的结果表明脑源性神经营养因子参与了双相障碍中抑郁的结局。回避危险与脑源性神经营养因子基因型没有相互作用,但它的影响仍然显著。鉴于许多因素可能影响药物治疗的反应,在药物遗传学研究中也需要考虑人格和其他个体特征的研究。